Ionis and Roche to develop RNAi AMD drug in $760m dealIonis and Roche have struck a deal worth up to $760 million (£575 million) to develop a drug Share XIonis and Roche to develop RNAi AMD drug in $760m dealhttps://pharmaphorum.com/news/ionis-and-roche-to-develop-rnai-amd-drug-in-760m-deal/
Number of UK clinical trials in decline since Brexit voteOngoing uncertainty and concern about Brexit has already cut the number of clinical trials carried out in the Share XNumber of UK clinical trials in decline since Brexit votehttps://pharmaphorum.com/news/number-of-uk-clinical-trials-in-decline-since-brexit-vote/
FDA gives go-ahead for CRISPR-based sickle cell disease trialDevelopment of a stem cell therapy for sickle cell disease from Vertex and development partner CRISPR therapeutics can Share XFDA gives go-ahead for CRISPR-based sickle cell disease trialhttps://pharmaphorum.com/news/fda-gives-go-ahead-for-crispr-based-sickle-cell-disease-trial/
New data sets up potential new gastro use for J&J’s StelaraJanssen’s Stelara has shown positive results in an ulcerative colitis (UC) trial, setting up a potential new indication Share XNew data sets up potential new gastro use for J&J’s Stelarahttps://pharmaphorum.com/news/new-data-sets-up-potential-new-gastro-use-for-jjs-stelara/
Novartis drug cuts serious complications in sickle cell diseaseNovartis’ developmental sickle cell disease drug crizanlizumab cut occurrences of a serious complication of the disease that can Share XNovartis drug cuts serious complications in sickle cell diseasehttps://pharmaphorum.com/news/novartis-drug-cuts-serious-complications-in-sickle-cell-disease/
UK biotech Orchard plans $172.5m US IPO to fund rare disease R&DUK biotech Orchard Therapeutics is planning a US IPO to expand use of its Strimvelis gene therapy, and Share XUK biotech Orchard plans $172.5m US IPO to fund rare disease R&Dhttps://pharmaphorum.com/news/uk-biotech-orchard-plans-172-5m-us-ipo-to-fund-rare-disease-rd/
Novartis chases untapped MS market with siponimodUS and European regulators have accepted filings for Novartis’s siponimod for secondary progressive multiple sclerosis (SPMS). The US Share XNovartis chases untapped MS market with siponimodhttps://pharmaphorum.com/news/novartis-chases-untapped-ms-market-with-siponimod/
Lilly unveils promising data from dual-action diabetes drugEli Lilly’s investigational diabetes drug has shown early promise as a possible aid to overcoming obesity in trial Share XLilly unveils promising data from dual-action diabetes drughttps://pharmaphorum.com/news/lilly-diabetes-unveils-promising-data-from-dual-action-diabetes-drug/
Trial shows Roche’s new flu drug helps reduce symptoms in at-risk patientsBaloxavir marboxil, a flu drug seen by Roche as a successor to Tamiflu, significantly sped time to relief Share XTrial shows Roche’s new flu drug helps reduce symptoms in at-risk patientshttps://pharmaphorum.com/news/trial-shows-roches-new-flu-drug-helps-reduce-symptoms-in-at-risk-patients/
Humira developer Winter among Nobel chemistry prize winnersA scientist who pioneered the technology used to discover the biggest selling drug in the world, AbbVie’s Humira, Share XHumira developer Winter among Nobel chemistry prize winnershttps://pharmaphorum.com/news/humira-developer-winter-among-nobel-chemistry-prize-winners/
Recardio ceases UK drug trials, blaming BrexitMedical research firm Recardio has ceased all of its drug trials in the UK over concerns about Brexit. Share XRecardio ceases UK drug trials, blaming Brexithttps://pharmaphorum.com/news/recardio-ceases-uk-drug-trials-blaming-brexit/
Alnylam rare disease drug may be delayedAlnylam may have to put hold off plans for an early FDA approval for its gene-silencing drug givosiran Share XAlnylam rare disease drug may be delayedhttps://pharmaphorum.com/news/alnylam-rare-disease-drug-may-be-delayed/
Alexion prepares filings for new rare disease use for SolirisAlexion is preparing filings in major markets for its rare disease drug Soliris in a new indication after Share XAlexion prepares filings for new rare disease use for Solirishttps://pharmaphorum.com/news/alexion-prepares-filings-for-new-rare-disease-use-for-soliris/
GSK TB vaccine shows promise, but more trials neededGlaxoSmithKline’s experimental TB vaccine has shown that it could help prevent the disease, but further research is needed Share XGSK TB vaccine shows promise, but more trials neededhttps://pharmaphorum.com/news/gsk-tb-vaccine-shows-promise-but-more-trials-needed/
TG Therapeutics cancer trial setback sends shares tumblingTG Therapeutics (TG) has suffered a setback in its blood cancer drug trial, as the data available was Share XTG Therapeutics cancer trial setback sends shares tumblinghttps://pharmaphorum.com/news/tg-therapeutics-cancer-trial-setback-sends-shares-tumbling/
UK public-private partnership to use AI to cut drug failure rateA UK R&D project has secured a government grant to help its artificial intelligence (AI)-based drug discovery project. Share XUK public-private partnership to use AI to cut drug failure ratehttps://pharmaphorum.com/news/uk-public-private-partnership-to-use-ai-to-cut-drug-failure-rate/
Sosei shares tank after safety issue with Alzheimer’s drugAllergan and Sosei’s experimental Alzheimer’s medicine has run into trouble – the companies have called a halt to Share XSosei shares tank after safety issue with Alzheimer’s drughttps://pharmaphorum.com/news/sosei-shares-tank-after-safety-issue-with-alzheimers-drug/
Novo Nordisk lays off 400 staff in R&D shake-upNovo Nordisk is laying off 400 people in Denmark and China so it can overhaul its R&D and Share XNovo Nordisk lays off 400 staff in R&D shake-uphttps://pharmaphorum.com/news/novo-nordisk-lays-off-400-staff-in-rd-shake-up/
